<DOC>
	<DOCNO>NCT02418195</DOCNO>
	<brief_summary>The purpose study examine whether neural-derived exosomal miRNAs differentially express specific suicidal ideation behavior , affect specific miRNA target pathway , associate suicidal behavior response ketamine . The follow group subject examine : 1 ) major depressive disorder ( MDD ) recent suicide attempt ( past 2 week ) , 2 ) MDD serious ideation ( past 7 day ) without recent suicide attempt ( past 6 month ) , 3 ) MDD without clinically significant suicidal ideation ( past 7 day ) recent suicide attempt ( past 6 month ) , 4 ) healthy control . Both suicidal non-suicidal MDD give ketamine ( 0.5 mg/kg , IV ) blood drawn predose , 30 min , 180 min , 24 hour , 14 day post-infusion measure change miRNAs .</brief_summary>
	<brief_title>miRNAs , Suicide , Ketamine - Plasma Exosomal microRNAs Novel Biomarkers Suicidality Treatment Outcome</brief_title>
	<detailed_description>Neural miRNAs responsive environmental , synaptic , pathological change actively secrete cell exosomes brain blood . These exosomes bear cell-type specific surface marker . Using neural specific surface marker , investigator successfully isolate neural-derived exosomes find exosomes enriched miRNAs/mRNAs express brain . Using novel approach investigator aim examine whether neural derive exosomal miRNAs differentially express specific suicidal ideation behavior , affect specific mRNA target pathway , associate suicidal behavior response ketamine . The follow group subject examine : 1 ) major depressive disorder ( MDD ) recent suicide attempt ( past 2 week ) , 2 ) MDD serious ideation ( past 7 day ) without recent suicide attempt ( past 6 month ) , 3 ) MDD without clinically significant suicidal ideation ( past 7 day ) suicide attempt past 6 month , 4 ) healthy control . Both suicidal non-suicidal MDD give ketamine ( 0.5 mg/kg , IV ) blood draw pre-infusion , 30 minute 180 minute post-infusion measure change miRNAs . Healthy control one-time blood draw . The investigator also propose parallel human postmortem brain study examine whether change miRNAs suicidality correspond miRNA change brain comparing dlPFC hippocampus MDD suicide , MDD non-suicide , control subject . With investigator attempt discover 1 ) whether suicidal ideation behavior associate difference expression specific miRNAs , 2 ) whether anti-suicidal/antidepressant effect ketamine associate miRNAs change , 3 ) whether miRNA/mRNA-regulatory pathway contribute suicide pathogenesis treatment response . Our study provide novel avenue development miRNAs `` molecular tool '' identify suicidality treatment response generate target base therapy treat devastate disorder .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>1 . Age 1865 2 . Physically healthy capable undergoing ketamine infusion 3 . Willing able provide inform consent 4 . Diagnosis MDE determine MINI ( MDD participant ) 5 . HAMD 21 score ≥ 16 ( MDD participant ) 6 . Suicide attempt occur within past 2 week ( MDD Participants Suicide Attempt ) 7 . For time frame past 7 day , CSSRS score ≥ 3 ( MDD Participants without Suicide Attempt , Suicidal Ideation ) 8 . For time frame past 7 day , CSSRS score &lt; 3 ( MDD Participants without Suicide Attempt , without SUicidal Ideation ) 1 . Pregnancy lactation 2 . Postpartum state ( within 2 month delivery miscarriage ) 3 . Homicide risk determine clinical interview 4 . A lifetime history psychotic disorder 5 . Any history dissociation dissociative disorder 6 . Bipolar disorder 7 . Pervasive developmental disorder 8 . Cognitive disorder 9 . Cluster A personality disorder 10 . Anorexia nervosa 11 . Treatment medication know affect glutamateNMDA receptor system ( e.g. , lamotrigine , acamprosate , memantine , riluzole , lithium ) 12 . Alcohol drug dependence ( except nicotine caffeine ) within last month use hallucinogen ( except cannabis ) , include phencyclidine last month 13 . Any known hypersensitivity serious adverse effect associate ketamine treatment 14 . Any clinicallysignificant medication condition therapy would preclude treatment ketamine , include : Recent myocardial infarction 15 . Unstable angina 16 . Active neoplasm past 6 month 17 . Immunosuppressive corticosteroid therapy within last month 18 . Chemotherapy 19 . Head injury loss consciousness past 6 month 20 . If subject report follow disorder : Rheumatoid arthritis Lupus erythematosus Autoimmune hepatitis Autoimmune peripheral neuropathy Autoimmune pancreatitis Behcet 's disease Chrohn 's disease Autoimmune glomerulonephritis Grave 's disease GuillainBarre syndrome ( active ) Hashimoto 's thyroiditis Autoimmune polymyositis polymyalgia ( fibromyalgia OK ) Myasthenia gravis Narcolepsy Polyarteritis nodosa Scleroderma Sjogren 's syndrome Transverse myelitis Wegener 's granulomatosis ( HIV Hepatitis OK stable ) 21 . Systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 90 screen 22 . A QTc &gt; 480 msec determine ECG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Ketamine</keyword>
	<keyword>Suicide Attempt</keyword>
	<keyword>Suicidal Ideation</keyword>
	<keyword>Suicidality</keyword>
</DOC>